C2N Diagnostics Expands Global Partnerships in United Kingdom on World Alzheimer’s Day, Joins Cambridge Cognition and The Alzheimer's Trust to Improve Alzheimer's Disease Diagnosis

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Women
Other Philanthropy
Seniors
Other Science
FDA
Research
Managed Care
Men
General Health
Family
Other Health
Consumer
Neurology
Medical Devices
Health Technology
Clinical Trials
Philanthropy
Health
Fund Raising
Foundation
Science
C2N Diagnostics, LLC

More Like This

Business Wire logo

C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom

C₂N Diagnostics, LLC Announces Investment From Eisai Inc.

PR Newswire associated0

ALZHEIMER'S DISEASE BLOOD TESTS COULD IMPROVE DIAGNOSIS IN PRIMARY CARE, SPEED RECRUITING FOR RESEARCH & REDUCE WAIT TIMES

Advances in science set to transform treatments for people living with dementia

PR Newswire associated0

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER'S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study

PR Newswire associated0

Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting

PR Newswire associated0

Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting